

Amendments to the Specification

On page 1, please insert the following paragraphs beginning on line 3:

--This is the U.S. National Stage of International Application No. PCT/GB2004/004330, filed October 12, 2004 (published in English under PCT Article 21(2)), which in turn claims the benefit of Great Britain patent application no. 0323813.6 filed October 13, 2003.

FIELD--

On page 1, please insert the following paragraph beginning on line 8:

--BACKGROUND--

On page 4, please insert the following paragraph beginning on line 9:

--SUMMARY--

Please amend the paragraphs beginning on page 14, line 9:

--BRIEF DESCRIPTION OF THE DRAWINGS

An embodiment of the invention will now be described by example only and with reference to the following figures:

Figure 1 is the nucleic acid sequence of glucosyltransferase 72E1 (SEQ ID NO: 1);

Figure 2 is the amino acid sequence of glucosyltransferase 72E1 (SEQ ID NO: 2);

Figure 3 is the nucleic acid sequence of glucosyltransferase 72E2 (SEQ ID NO: 3);

Figure 4 is the amino acid sequence of glucosyltransferase 72E2 (SEQ ID NO: 4);

Figure 5 is the nucleic acid sequence of glucosyltransferase 72E3 (SEQ ID NO: 5);

Figure 6 is the amino acid sequence of glucosyltransferase 72E3 (SEQ ID NO: 6);

Figure 7 illustrates examples of monolignols and their modification by the glucosyltransferase 72E1 and 72E2; and

Figure 8a A 248 bp UTG72E1 cDNA fragment (SEQ ID NO: 13) was amplified using oligos 72E1-5(XhoI/XmaI) (CTCGAGCCCGGGATGAAGATTACAAAAC; SEQ ID NO: 7) and 72E1-3(5-E3) (ATCTTGTCACCACAAAGGCTGATGGGTCG; SEQ ID NO: 8); Figure 8b A 234 bp UTG72E3 cDNA fragment (SEQ ID NO: 14) was amplified using oligos 72E3-5(3-E1) (CGACCCATCAGCCTTTGTGGTGACCAAGAT; SEQ ID NO: 9) and 72E3-3(5-E2) (GGTATAGCGAGTGGGTTTCGTTGCACTGTG; SEQ ID NO: 10); Figure 8c A 247 bp UTG72E2 cDNA fragment (SEQ ID NO: 15) was amplified using oligos 72E2-5(3-E3) (CACAGTGCAACGAAACCCACTCGCTATACC; SEQ ID NO: 11) and 72E2-3(XbaI/SwaI) (ATTAAATTCTAGAGATGATTGTATCGGTCTG; SEQ ID NO: 12) nucleic acid sequences are presented in Figures 8a-8c.--

Please insert the Abstract, submitted herewith on a separate page, as page 22 at the end of the application.

Please replace the previous sequence listing with pages 1-12 of the enclosed sequence listing.